ReviewBlood science (Baltimore, Md.)2022

A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia.

Hao Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.